Related Experiment Videos
[Pharmacokinetics of ceftazidime in the cerebrospinal fluid]
1Clinique des Maladies infectieuses, Hôpital Saint-Louis, Paris.
Abstract:
A compound potentially effective in the treatment of meningitis should reach high concentrations in CSF. In animal experimental models, ceftazidime levels of 5-25 micrograms/ml were demonstrated during administration of doses generating serum levels similar to those achieved in humans. Human studies later confirmed CSF levels of 5-10 micrograms/ml in patients with meningitis. Ceftazidime CSF kinetic properties are adequate for use of this compound in patients with meningitis due to susceptible organisms.
Insights
Ceftazidime effectively treats meningitis by achieving high cerebrospinal fluid (CSF) concentrations. Studies in animals and humans confirm adequate CSF levels for treating meningitis caused by susceptible bacteria.
Area of Science:
- Pharmacokinetics and infectious disease research.
- Clinical pharmacology of antibiotics.
Context:
- Meningitis treatment requires antibiotics to penetrate the cerebrospinal fluid (CSF).
- Ceftazidime is a potential therapeutic agent for bacterial meningitis.
Purpose:
- To evaluate the CSF penetration and kinetic properties of ceftazidime.
- To determine if ceftazidime achieves therapeutic concentrations in the CSF for meningitis treatment.
Summary:
- Animal models showed ceftazidime CSF levels of 5-25 µg/ml at human-equivalent doses.
- Human studies confirmed therapeutic CSF concentrations of 5-10 µg/ml in meningitis patients.
- Ceftazidime demonstrates adequate CSF kinetic properties for meningitis therapy.
Impact:
- Supports the clinical use of ceftazidime in treating meningitis.
- Provides evidence for effective antibiotic penetration in the central nervous system.
- Informs antibiotic selection for bacterial meningitis management.